Department of Emergency Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei 230031, Anhui, PR China.
Department of Emergency Surgery, the First Affiliated Hospital of Anhui Medical University, High-tech Hospital District, Hefei 230088, Anhui, PR China.
Pharmacol Res. 2021 Jul;169:105611. doi: 10.1016/j.phrs.2021.105611. Epub 2021 Apr 18.
Hepatocellular carcinoma (HCC), one of the main contributors to cancer-associated deaths globally, is characterized by high invasiveness. Herein, we studied the molecular mechanisms underlying ten-eleven translocation 1 (TET1)-mediated autophagy in HCC. Following data mining using GSE101728, GSE14520 and GSE138178, TET1 was screened out, and the differential expression of TET1 was verified by bioinformatics analysis. TET1, one of the prognostic markers in HCC, was poorly expressed in HCC. Through functional experiments, we determined that upregulation of TET1 inhibited the proliferation, migration, invasion, tumorigenesis, metastasis and inflammatory factors of HCC cells, and promoted cell autophagy and apoptosis. Mechanistically, TET1 activated miR-34a by demethylating miR-34a. BTB domain and CNC homology 1 (BACH1) was identified as the target gene of miR-34a. Notably, Downregulation of miR-34a increased cellular inflammatory factors and decreased autophagy in the presence of TET1, while declines in BACH1 suppressed cellular inflammatory factors and enhanced autophagy in the presence of miR-34a inhibitor. BACH1 negatively regulated the p53 pathway. In conclusion, TET1 is a tumor suppressor in the progression of HCC by regulating the miR-34a/BACH1/p53 axis, and may contribute to the improvement of HCC prognosis and therapy.
肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一,其特征为高侵袭性。在此,我们研究了十号染色体缺失的磷酸酶-张力蛋白同源物(TET)1 介导的自噬在 HCC 中的分子机制。通过使用 GSE101728、GSE14520 和 GSE138178 进行数据挖掘,筛选出 TET1,并通过生物信息学分析验证 TET1 的差异表达。TET1 是 HCC 的预后标志物之一,在 HCC 中表达水平较低。通过功能实验,我们确定上调 TET1 可抑制 HCC 细胞的增殖、迁移、侵袭、致瘤性、转移和炎症因子,并促进细胞自噬和凋亡。机制上,TET1 通过去甲基化 miR-34a 激活 miR-34a。双 BRCT 结构域和 CNC 同源性 1(BACH1)被鉴定为 miR-34a 的靶基因。值得注意的是,在存在 TET1 的情况下,下调 miR-34a 会增加细胞炎症因子并减少自噬,而下调 BACH1 会抑制细胞炎症因子并增强存在 miR-34a 抑制剂时的自噬。BACH1 负调控 p53 通路。总之,TET1 通过调节 miR-34a/BACH1/p53 轴在 HCC 的进展中起抑癌作用,可能有助于改善 HCC 的预后和治疗。